Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amgen Stock Dives
Amgen Stock Dives After Weight-Loss Drug Data. Here’s What to Know.
The pharmaceutical company's MariTide treatment performed well in a Phase 2 study but not as well as Wall Street expected.
Amgen's weight-loss drug fails to impress in study; shares plunge
Amgen's experimental drug MariTide helped overweight or obese patients shed up to 20% of their body weight in a mid-stage trial, but the results failed to meet lofty investor expectations and shares of the biotech company tumbled about 12% on Tuesday.
New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.
3d
What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
3h
on MSN
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
4d
Amgen posts mid-stage data for weight loss therapy
Amgen (AMGN) stock slips as company posts mid-stage trial data for weight loss therapy MariTide. Rivals Eli Lilly (LLY) and ...
3d
Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...
2d
Amgen price target lowered to $330 from $360 at RBC Capital
RBC Capital analyst Gregory Renza lowered the firm’s price target on Amgen (AMGN) to $330 from $360 and keeps an Outperform rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback